The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.
Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain
Open accessAbstract
Cannabinoid-based medicines have therapeutic potential for the treatment of pain. Augmentation of levels of endocannabinoids with inhibitors of fatty acid amide hydrolase (FAAH) is analgesic in models of acute and inflammatory pain states. The aim of this study was to determine whether local inhibition of FAAH alters nociceptive responses of spinal neurons in the spinal nerve ligation model of neuropathic pain. Electrophysiological studies were performed 14-18 d after spinal nerve ligation or sham surgery, and the effects of the FAAH inhibitor cyclohexylcarbamic acid 3-carbamoyl biphenyl-3-yl ester (URB597) on mechanically evoked responses of spinal neurons and levels of endocannabinoids were determined. Intraplantar URB597 (25 microg in 50 microl) significantly (p < 0.01) attenuated mechanically evoked responses of spinal neurons in sham-operated rats. Effects of URB597 were blocked by the cannabinoid 1 receptor (CB1) antagonist AM251 [N-1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide] (30 microg in 50 microl) and the opioid receptor antagonist naloxone. URB597 treatment increased levels of anandamide, 2-arachidonyl glycerol, and oleoyl ethanolamide in the ipsilateral hindpaw of sham-operated rats. Intraplantar URB597 (25 microg in 50 microl) did not, however, alter mechanically evoked responses of spinal neurons in spinal nerve ligated (SNL) rats or hindpaw levels of endocannabinoids. Intraplantar injection of a higher dose of URB597 (100 microg in 50 microl) significantly (p < 0.05) attenuated evoked responses of spinal neurons in SNL rats but did not alter hindpaw levels of endocannabinoids. Spinal administration of URB597 attenuated evoked responses of spinal neurons and elevated levels of endocannabinoids in sham-operated and SNL rats. These data suggest that peripheral FAAH activity may be altered or that alternative pathways of metabolism have greater importance in SNL rats.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the same study, spinal administration of URB597 was equally efficacious at attenuating mechanically-evoked responses and increasing levels of endogenous cannabinoids in SNL and sham rats and these effects were CB1-mediated.92”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [92]
In the citing paper
“The antinociceptive effects of URB597 were blocked by a CB1-specific antagonist in both sham and SNL rats.92”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [92]
In the citing paper
“Low doses of locally injected URB597 (i.pl.) reduced mechanically-evoked responses of WDR neurons and increased endocannabinoid levels in ipsilateral paw tissue of sham operated rats.92”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [92]
In the citing paper
“A four-fold higher dose was required for reduction of mechanically-evoked WDR neuronal responses in SNL rats; these rats showed no corresponding increase in endocannabinoid levels, suggesting that contributions of FAAH to endocannabinoid metabolism may be modified under conditions of neuropathic nociception.92”
From Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside (2009) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quantitative assessment of tactile allodynia in the rat paw
Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M., & Yaksh, T. L. (1994) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(94)90144-9 · Cited by 7,740
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Ho Kim, S., & Mo Chung, J. (1992) · Pain · doi:10.1016/0304-3959(92)90041-9 · Cited by 3,069
International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors
Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., et al. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.161 · Cited by 2,819
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Brain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Cravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Modulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293
Control of pain initiation by endogenous cannabinoids
Calignano, A., Rana, G. L., Giuffrida, A., & Piomelli, D. (1998) · Nature · doi:10.1038/28393 · Cited by 1,069
Research works printed but not linked: 1
- Wilson AW Clayton NM Medhurst SJ Bountra C Chessel IP (2004) The FAAH inhibitor URB597 reverses inflammatory pain through a CB1 receptor mediated mechanism. Proceedings of the British Pharmacological Society, Retrieved November 21, 2006 from http://www.pA2online.org/Vol2Issue4abst049P.html .
Cited by
Sorted by citations
Items 101–164 of 164
Palmer, J. A., Higuera, E. S., Chang, L., & Chaplan, S. R. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.04.047 · Cited by 26
Tuberoinfundibular peptide of 39 residues (TIP39) signaling modulates acute and tonic nociception
Dimitrov, E. L., Petrus, E., & Usdin, T. B. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.08.004 · Cited by 26
Watabiki, T., Tsuji, N., Kiso, T., 徹, 小., Narazaki, F., & Kakimoto, S. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.10.007 · Cited by 23
Functional blockage of the cannabinoid receptor type 1 evokes a kappa‐opiate‐dependent analgesia
Sáez-Cassanelli, J. L., Fontanella, G. H., Delgado-Garcia, J. M., & Carrión, Á. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05000.x · Cited by 22
Metabolism of Anandamide into Eoxamides by 15‐Lipoxygenase‐1 and Glutathione Transferases
Forsell, P. K. A. L., Brunnström, Å., Johannesson, M., & Claesson, H. (2012) · Lipids · doi:10.1007/s11745-012-3684-z · Cited by 21
Anandamide in primary sensory neurons: too much of a good thing?
Valente, J. D. S., Varga, A., Ananthan, K., Khajuria, A., & Nagy, I. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12467 · Cited by 20
Bosier, B., Doyen, P. J., Brolet, A., Muccioli, G. G., Ahmed, E., Desmet, N., Hermans, E., & Deumens, R. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13324 · Cited by 20
Bradford, D., Stirling, A., Ernault, É., Liosatos, M., Tracy, K. A., Moseley, J. L., Blahunka, P. C., & Smith, M. D. (2017) · Pain Medicine · doi:10.1093/pm/pnx046 · Cited by 21
Alterations in the Anandamide Metabolism in the Development of Neuropathic Pain
Małek, N., Kucharczyk, M. W., & Starowicz, K. (2014) · BioMed Research International · doi:10.1155/2014/686908 · Cited by 19
Valente, J. D. S., Varga, A., Torres-Pérez, J. V., Jenes, Á., Wahba, J., Mackie, K., Cravatt, B. F., Ueda, N., Tsuboi, K., Sántha, P., et al. (2016) · The Journal of Comparative Neurology · doi:10.1002/cne.24154 · Cited by 17
Cannabis constituents for chronic neuropathic pain; reconciling the clinical and animal evidence
Sokolaj, E. E., Assareh, N., Anderson, K. E., Aubrey, K. R., & Vaughan, C. W. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15964 · Cited by 16
Dönertaş, B., Ünel, Ç. Ç., & Erol, K. (2018) · Journal of Experimental Pharmacology · doi:10.2147/jep.s162059 · Cited by 14
Cisneros, J. A., Vandevoorde, S., Ortega‐Gutiérrez, S., Paris, C., Fowler, C. J., & López-Rodríguez, M. L. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070642y · Cited by 14
Switching cannabinoid response from CB2 agonists to FAAH inhibitors
Tourteau, A., Leleu‐Chavain, N., Body–Malapel, M., Andrzejak, V., Barczyk, A., Djouina, M., Rigo, B., Desreumaux, P., Chavatte, P., & Millet, R. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.01.056 · Cited by 12
Schaffler, K., Yassen, A., Reeh, P. W., & Passier, P. C. C. M. (2017) · Pain Medicine · doi:10.1093/pm/pnx281 · Cited by 12
Endocannabinoid modulation of jejunal afferent responses to LPS
Donovan, J., & Grundy, D. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01961.x · Cited by 11
Roa‐Coria, J. E., Navarrete‐Vázquez, G., Fowler, C. J., Flores‐Murrieta, F. J., Déciga‐Campos, M., & Granados‐Soto, V. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.09.024 · Cited by 11
Czikora, Á., Lizanecz, E., Boczán, J., Daragó, A., Papp, Z. L., Edes, I. F., & Tóth, A. (2012) · Life Sciences · doi:10.1016/j.lfs.2011.12.016 · Cited by 10
Effect of chiral polyhydrochromenes on cannabinoid system
Ли-Жуланов, Н. С., Ильина, И. В., Chicca, A., Schenker, P., Patrusheva, O. S., Nazimova, E. V., Викторовна, К. Д., Krasavin, M., Volcho, K. P., & Salakhutdinov, N. F. (2019) · Medicinal Chemistry Research · doi:10.1007/s00044-019-02294-9 · Cited by 10
Almeida, R. T., Romero, T. R. L., Castor, M. G. M. E., Galdino, G. S., Perez, A. C., & Duarte, I. D. G. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.07.004 · Cited by 10
Targeting the Cannabinoid System to Produce Analgesia
Sagar, D. R., Jhaveri, M. D., & Chapman, V. (2009) · Current topics in behavioral neurosciences · doi:10.1007/978-3-540-88955-7_11 · Cited by 10
Okine, B. N., Gaspar, J. C., Madasu, M. K., Olango, W. M., Harhen, B., Roche, M., & Finn, D. P. (2016) · Brain Research · doi:10.1016/j.brainres.2016.11.022 · Cited by 9
Chapter 4.5 The endocannabinoid system and anxiety responses
Bortolato, M., & Piomelli, D. (2008) · Handbook of Behavioral Neuroscience · doi:10.1016/s1569-7339(07)00014-8 · Cited by 7
Anandamide-Mediated Modulation of Nociceptive Transmission at the Spinal Cord Level
Spicarova, D., & Paleček, J. (2024) · Physiological Research · doi:10.33549/physiolres.935371 · Cited by 7
Gholami, S., Bordbar, A., & Akvan, N. (2016) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2016.07.024 · Cited by 7
Eriksen, G. S., Jacobsen, L. M., Mahmood, A., Pedersen, L. M., & Gjerstad, J. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.11.009 · Cited by 7
Okine, B. N., Spicer, C. H., Millns, P. J., Bennett, A. J., & Chapman, V. (2015) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2015.06.004 · Cited by 6
Effect of Fatty Acid Amide Hydrolase Inhibitor URB597 on Orofacial Pain Perception in Rats
Zubrzycki, M., Zubrzycka, M., Wysiadecki, G., Szemraj, J., Jerczyńska, H., & Stasiołek, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094665 · Cited by 6
Inhibition of Fatty Acid Amide Hydrolase: A Potential Treatment for Neuropathic Pain: Figure 1.
Trang, T. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0583-07.2007 · Cited by 6
Endocannabinoids, “New-Old” Mediators of Stress Homeostasis
Hauer, D., Tóth, R., & Schelling, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-16996-1_10 · Cited by 5
Doehring, A., Geißlinger, G., & Lötsch, J. (2007) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2007.06.001 · Cited by 5
Electrophysiology of Endocannabinoid Signaling
Musella, A., & Centonze, D. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2728-0_38 · Cited by 4
Carr, D., Gunari, S., Gorostiza, G., Mercado, M., Pavana, L., Duong, L., Gomez, K., Salinas, S., Garcia, C., Tsang, A., et al. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102009 · Cited by 3
Shimoyama, H., Tsuda, M., Masuda, T., Yoshinaga, R., Tsukamoto, K., Tozaki‐Saitoh, H., & Inoue, K. (2014) · The Open Pain Journal · doi:10.2174/1876386301407010001 · Cited by 3
Carrascosa, A. J., García‐Gutiérrez, M. S., Saldaña, R., & Manzanares, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117054 · Cited by 2
Anandamide and Other Acylethanolamides
Petrosino, S., & Marzo, V. D. (2009) · Springer eBooks · doi:10.1007/978-0-387-30378-9_5 · Cited by 2
Takizawa, M., Cerneus, D. P., Michon, I. N., Rijnders, S., van der Heide, D., Meijer, J., Stoelzel, M., & Sato, Y. Z. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01402-1 · Cited by 2
The Management of Neuropathic Pain
Toth, C., & Moulin, D. E. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139152211.019 · Cited by 1
Cannabinoid Receptor Mediated Analgesia: Novel Targets for Chronic Pain States
Chapman, V., Kendall, D. A., & Sagar, D. R. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0226-9_15 · Cited by 1
Endocannabinoids, “New-Old” Mediators of Stress Homeostasis
Hauer, D., Tóth, R., & Schelling, G. (2011) · Springer eBooks · doi:10.1007/978-3-642-22272-6_8 · Cited by 1
The ever-expanding world of the endocannabinoids: A concise introduction
Piscitelli, F., & Marzo, V. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417041-4.00024-2 · Cited by 1
Targeting the Endocannabinoid Metabolic Enzymes to Reduce Inflammatory Pain
Ghosh, S. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/ngv2-th75 · Cited by 1
Control of analgesic and anti-inflammatory pathways by fatty acid amide hydrolase
Long, J. H. (2012) · Cited by 1
The cellular processing of the endocannabinoid anandamide and its pharmacological manipulation
Thors, L. (2009) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Study of the interaction between 3,4 methylenedioximethamphetamine and the endocannabinoid system
Touriño, C. (2009) · Repositori digital de la UPF (Universitat Pompeu Fabra)
Recent developments in the molecular biology of pain
Wollemann, M. (2011)
Removal of Endocannabinoids by the Body: Mechanisms and Therapeutic Possibilities
Fowler, C. J., & Thors, L. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3_3
Ware, M. A. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139152211.022
Philosophy at Virginia Commonwealth University.
Booker, L. (2011)
Endocannabinoid modulation of capsaicin-induced behavioral hypersensitivity
Spradley, J. M. (2010)
Metabolism of N ‐Acylethanolamines: To Phase II and Back Again
Karlsson, J., & Fowler, C. J. (2017) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0027664
Sekar, S. (2018) · Queensland University of Technology · doi:10.5204/thesis.eprints.116166
Takizawa, M., Cerneus, D. P., Michon, I. N., Rijnders, S., Meijer, J., Someya, A., & Sato, Y. Z. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01451-6
Schlosburg, J. E. (2010) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/tss0-g006
(2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3282efeb3b
Kim, J. S., Franchini, L., Yudin, Y. K., Denissiouk, A. N., Rohács, T., Orlandi, C., & Das, A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.17.681057
The Endocannabinoid System’s Contribution to Placebo AnalgesiaPreprint
Tomin, R., Murray, K., Hadjis, G. E., Khalil, O., Sexton, C. A., Bourke, S. L., Khan, J. S., Finn, D. P., Atlas, L. Y., & Moayedi, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.25.707676
BindingDB (2008) · UC San Diego · doi:10.7270/q25d8q58
BindingDB (2008) · UC San Diego · doi:10.7270/q2jh3jgs
BindingDB Entry 50043908: Switching cannabinoid response from CB(2) agonists to FAAH inhibitors.
BindingDB (2014) · UC San Diego · doi:10.7270/q2319xcd
Targeting the endocannabinoid system to reduce nociception
Booker, L. (2011) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/j2fe-wf53
Metadata
- Authors
- Jhaveri, M. D., Richardson, D., Kendall, D. A., Barrett, D. A., & Chapman, V.
- Affiliations
- University of Nottingham (GB)
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-12-20
- Volume
- 26
- Issue
- 51
- Pages
- 13318-13327
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6674985
- OpenAlex
- W2037393750
- Cited by
- 159
- References
- 76
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 5 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 7 · 2015: 5 · 2014: 11 · 2013: 9 · 2012: 14
- FWCI
- 12.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Nottingham ePrints (University of Nottingham) (submittedVersion, cc-by)
- Repository@Nottingham (University of Nottingham) (submittedVersion, other-oa)
- Funders
- Wellcome Trust
- Directorate for Biological Sciences
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
- Keywords
- fatty acid amide hydrolase inhibition, neuropathic pain, spinal nerve ligation, URB597, endocannabinoids, anandamide, 2-arachidonoylglycerol, oleoylethanolamide, cannabinoid 1 receptor, AM251, naloxone, mechanical nociception, spinal cord neurons, analgesia
- MeSH terms
- Fatty Acid Amide Hydrolases, Amidohydrolases, Analgesics, Animals, Benzamides, Carbamates, Disease Models, Animal, Enzyme Inhibitors, Injections, Spinal, Male, Pain, Pain Measurement, Rats, Sprague-Dawley, Receptor, Cannabinoid, CB1, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
